Horizon prepares to dive into chilly IPO market

Horizon Pharma will reportedly make its bid to go public this week in an effort to raise up to $66 million. The company, which develops meds for arthritis and pain, will try and offer 5.5 million shares for between $10 and $12 each. So far this year there has been a rising number of IPOs, but many have been forced to cut their share price as investors steered clear of the kind of high risks associated with biotechnology. Story

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.